A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections

Stephani Leflore, Peter L. Anderson, Courtney V. Fletcher

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The objective of this article is to review and evaluate risks and benefits associated with the use of aciclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was found through a MEDLINE search using keywords: herpes simplex virus, genital herpes, herpes labialis, aciclovir and acyclovir. Selected articles were randomised, double-blind, placebo-controlled, clinical trials. 30 such trials involving 3364 persons were evaluated. All articles were reviewed by the authors and the data were extracted and summarised. In both immunocompetent and immunocompromised hosts, aciclovir therapy demonstrated a high degree of clinical efficacy. None of the studies reported statistically significant differences between aciclovir and placebo for mild or major adverse events. This evaluation found that aciclovir is both effective and well tolerated for treatment and prophylaxis of genital, oral and mucocutaneous HSV infections in immunocompetent and immunocompromised patients. In most clinical scenarios, the benefit of aciclovir exceeded any risks by a comfortable margin. The availability of aciclovir as a generic preparation further improves the benefit to cost ratio.

Original languageEnglish (US)
Pages (from-to)131-142
Number of pages12
JournalDrug Safety
Volume23
Issue number2
DOIs
StatePublished - Jan 1 2000

Fingerprint

Acyclovir
Virus Diseases
Simplexvirus
Viruses
Immunocompromised Host
Therapeutics
Herpetic Stomatitis
Herpes Labialis
Placebos
Herpes Genitalis
Controlled Clinical Trials
MEDLINE
Cost-Benefit Analysis
Availability

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. / Leflore, Stephani; Anderson, Peter L.; Fletcher, Courtney V.

In: Drug Safety, Vol. 23, No. 2, 01.01.2000, p. 131-142.

Research output: Contribution to journalReview article

@article{acc1afb7a91443ba8c6f56791bbd29e7,
title = "A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections",
abstract = "The objective of this article is to review and evaluate risks and benefits associated with the use of aciclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was found through a MEDLINE search using keywords: herpes simplex virus, genital herpes, herpes labialis, aciclovir and acyclovir. Selected articles were randomised, double-blind, placebo-controlled, clinical trials. 30 such trials involving 3364 persons were evaluated. All articles were reviewed by the authors and the data were extracted and summarised. In both immunocompetent and immunocompromised hosts, aciclovir therapy demonstrated a high degree of clinical efficacy. None of the studies reported statistically significant differences between aciclovir and placebo for mild or major adverse events. This evaluation found that aciclovir is both effective and well tolerated for treatment and prophylaxis of genital, oral and mucocutaneous HSV infections in immunocompetent and immunocompromised patients. In most clinical scenarios, the benefit of aciclovir exceeded any risks by a comfortable margin. The availability of aciclovir as a generic preparation further improves the benefit to cost ratio.",
author = "Stephani Leflore and Anderson, {Peter L.} and Fletcher, {Courtney V.}",
year = "2000",
month = "1",
day = "1",
doi = "10.2165/00002018-200023020-00004",
language = "English (US)",
volume = "23",
pages = "131--142",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections

AU - Leflore, Stephani

AU - Anderson, Peter L.

AU - Fletcher, Courtney V.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The objective of this article is to review and evaluate risks and benefits associated with the use of aciclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was found through a MEDLINE search using keywords: herpes simplex virus, genital herpes, herpes labialis, aciclovir and acyclovir. Selected articles were randomised, double-blind, placebo-controlled, clinical trials. 30 such trials involving 3364 persons were evaluated. All articles were reviewed by the authors and the data were extracted and summarised. In both immunocompetent and immunocompromised hosts, aciclovir therapy demonstrated a high degree of clinical efficacy. None of the studies reported statistically significant differences between aciclovir and placebo for mild or major adverse events. This evaluation found that aciclovir is both effective and well tolerated for treatment and prophylaxis of genital, oral and mucocutaneous HSV infections in immunocompetent and immunocompromised patients. In most clinical scenarios, the benefit of aciclovir exceeded any risks by a comfortable margin. The availability of aciclovir as a generic preparation further improves the benefit to cost ratio.

AB - The objective of this article is to review and evaluate risks and benefits associated with the use of aciclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was found through a MEDLINE search using keywords: herpes simplex virus, genital herpes, herpes labialis, aciclovir and acyclovir. Selected articles were randomised, double-blind, placebo-controlled, clinical trials. 30 such trials involving 3364 persons were evaluated. All articles were reviewed by the authors and the data were extracted and summarised. In both immunocompetent and immunocompromised hosts, aciclovir therapy demonstrated a high degree of clinical efficacy. None of the studies reported statistically significant differences between aciclovir and placebo for mild or major adverse events. This evaluation found that aciclovir is both effective and well tolerated for treatment and prophylaxis of genital, oral and mucocutaneous HSV infections in immunocompetent and immunocompromised patients. In most clinical scenarios, the benefit of aciclovir exceeded any risks by a comfortable margin. The availability of aciclovir as a generic preparation further improves the benefit to cost ratio.

UR - http://www.scopus.com/inward/record.url?scp=0033854454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033854454&partnerID=8YFLogxK

U2 - 10.2165/00002018-200023020-00004

DO - 10.2165/00002018-200023020-00004

M3 - Review article

C2 - 10945375

AN - SCOPUS:0033854454

VL - 23

SP - 131

EP - 142

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 2

ER -